PARP1 and lung adenocarcinoma: This study therefore investigates how PARP inhibitor talazoparib, in combination with radiation, influences senescence and mitochondrial membrane potential through p21 in lung adenocarcinoma cells, aiming to identify strategies that improve therapeutic durability and minimize tumor relapses.